Showing 2991-3000 of 5771 results for "".
- Ripple Therapeutics Partners with AbbVie to Develop Intracameral Implant for Glaucomahttps://modernod.com/news/ripple-therapeutics-partners-with-abbvie-to-develop-intracameral-implant-for-glaucoma/2482444/Ripple Therapeutics announced a collaboration and option-to-license agreement with AbbVie to advance the development of RTC-620, a fully biodegradable, sustained-release intracameral implant designed to reduce IOP in patients suffering from open-angle glaucoma (OAG) or ocular hypertensi
- Nanoscope Plans Phase 3 Trial of MCO-010 to Treat Stargardt Macular Degenerationhttps://modernod.com/news/nanoscope-plans-phase-3-trial-of-mco-010-to-treat-stargardt-macular-degeneration/2482440/Nanoscope Therapeutics announced the completion of an End-of-phase 2 (EOP2) meeting with the FDA for its clinical program evaluating MCO-010 for the treatment of severe vision loss caused by Stargardt macular degeneration (SMD), supporting advancement of MCO-010 to a phase 3 registrational trial.
- Iantrek Publishes Clinical Results of Uveoscleral Outflow Technology for Open-Angle Glaucomahttps://modernod.com/news/iantrek-publishes-clinical-results-of-uveoscleral-outflow-technology-for-open-angle-glaucoma/2482437/Iantrek announced the publication of clinical results highlighting the efficacy of Iantrek’s uveoscleral outflow technology for the treatment of glaucoma. The results, published in the Journal of Clinical Medici
- iCare Launches ST500 Slit-Lamp Based Tonometerhttps://modernod.com/news/icare-launches-st500-slit-lamp-based-tonometry/2482436/iCare announced the release of the iCare ST500, a slit-lamp-based tonometer that brings the features of iCare’s rebound tonometry technology into a modern design. The iCare ST500 offers an advanced solution for IOP measurement, combining extreme ease of u
- Alcon Unveils SMARTCataract DX and Ngenuity 1.5 at ESCRShttps://modernod.com/news/alcon-unveils-innovations-at-escrs-including-smartcataract-dx-and-ngenuity-15/2482433/Alcon is introducing new technologies at the European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting aimed at improving efficiency and outcomes in cataract surgery. Among the announcements are the unveiling of the SMARTCataract DX digital planning solution and the upgraded Nge
- Ocuphire Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopiahttps://modernod.com/news/ocuphire-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-075-for-presbyopia/2482432/Ocuphire Pharma announced the first dosing of participants in its VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. Ocuphire’s phentolamine ophthalmic solution 0.75% is being developed as a potential alternative t
- Atsena Therapeutics Publishes 12-Month Safety and Efficacy Data from Phase 1/2 Trial of ATSN-101 in LCA1https://modernod.com/news/atsena-therapeutics-publishes-12-month-safety-and-efficacy-data-from-phase-12-trial-of-atsn-101-in-lca1/2482431/Atsena Therapeutics announced 12-month safety and efficacy results from its phase 1/2 clinical trial of ATSN-101, an investigational gene therapy for Leber congenital amaurosis (LCA1), a rare inherited retinal disease causing severe vision impairment or blindness from infancy. The findi
- Aurion Biotech to Present at ESCRS and Ophthalmology Futures European Forumhttps://modernod.com/news/aurion-biotech-to-present-at-escrs-and-ophthalmology-futures-european-forum/2482430/Aurion Biotech announced its upcoming participation in the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), September 6-10, 2024, in Barcelona. The company will showcase clinical data on its allogeneic cell therapy drug candidate, AURN001. Aurion w
- Ciliatech to Present 36-Month Follow-Up Results on Intercil Uveal Spacer at Ophthalmology Futures European Forumhttps://modernod.com/news/ciliatech-to-present-36-month-follow-up-results-on-intercil-uveal-spacer-at-ophthalmology-futures-european-forum/2482427/Ciliatech has announced that it will reveal the combined 36-month follow-up results of its SAFARI I & II clinical trials at the Ophthalmology Futures European Forum on September 5. The company will share data on its Intercil Uveal Spacer, a Cilioscleral Interpositioning Device (CID) designed
- PulseSight Therapeutics Establishes International Scientific and Clinical Advisory Boardhttps://modernod.com/news/pulsesight-therapeutics-establishes-international-scientific-and-clinical-advisory-board/2482424/PulseSight Therapeutics announced the formation of a Scientific and Clinical Advisory Board (SAB) composed of internationally recognized experts in ophthalmology from Europe, the US, and Australia with extensive experience in both fundamental and clinical research in retinal and macular